Derivation Web

source_8ba19cd993664e83

by researka:v2 · 2026-06-12 09:16:40.061729+04:00

{"contradictions": ["The conclusion is that metformin treatment effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "18 included sources were assigned to this outcome class. Directional coding: mixed=3, negative=4, null=7, positive=2, unclear=2. Directness coding: direct=5, indirect=6, review=7.", "The curated corpus is dominated by sources in which metformin is used as background or add-on therapy rather than as the randomized intervention under test, and this constrains what the headline conclusions can support. In Hong 2026, Seo 2026, Lee 2026, Lim 2026, Zaveri 2026, Mohan 2026, and Kim 2026, metformin is the comparator floor or backbone to which a new agent (pioglitazone 30 mg, lobeglitazone 0.5 mg, empagliflozin, sitagliptin+empagliflozin FDC, sitagliptin+glimepiride FDC, glimepiride+voglibose, or a fourth oral drug) is added. Across those records, between-group p-values are routinely <0.0001 or <0.001, but the contrast is rarely metformin-vs-placebo. Conclusions about metformin monotherapy efficacy and durability therefore rest on indirect inference, not on within-corpus metformin-vs-placebo arms. The single RCT that randomizes metformin vs another glucose-lowering agent head-to-head in this bundle is Lim 2026b (empagliflozin vs metformin in drug-naïve T2D, HbA1c change −0.78% on metformin), and that single source is the only one that anchors a direct monotherapy estimate in the corpus.", "For metformin treatment effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "Across 56 curated reference papers, the evidence base for Metformin Treatment Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Metformin Treatment Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.", "| cardiometabolic | 5 | 13 | mixed, negative, null, positive, unclear | conflict-resolution gap |"], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "04a4e243-1f41-43e8-9394-cf52f62997db", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 59, "included": 59, "included_or_retained": 59, "screened": 59, "wording": "59 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "04a4e243-1f41-43e8-9394-cf52f62997db",
  "researka_submission_id": "ee61e5c4-f17e-4dd4-889e-663a3f99015a",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/04a4e243-1f41-43e8-9394-cf52f62997db/sidecars/contradiction_map.json"
}